1
40
5
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2174/1568009617666161121123948" target="_blank" rel="noreferrer noopener">http://doi.org/10.2174/1568009617666161121123948</a>
Pages
479–485
Issue
5
Volume
17
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer.
Publisher
An entity responsible for making the resource available
Current cancer drug targets
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
1905-7
Subject
The topic of the resource
Female; Humans; Animals; Mice; Apoptosis; Cell Line; ADME; Antineoplastic Agents/*therapeutic use; brain cancer; Brain Neoplasms/*drug therapy/pathology/*secondary; Breast Neoplasms/*pathology; chemotherapy; CNS; distribution; drug discovery; Drug resistance; Tumor
Creator
An entity primarily responsible for making the resource
Venishetty Vinay K; Geldenhuys Werner J; Terell-Hall Tori B; Griffith Jessica I G; Sondag Gregory R; Safadi Fayez F; Lockman Paul R
Description
An account of the resource
BACKGROUND: Brain cancer from metastasized breast cancer has a high mortality rate in women. The treatment of lesions is hampered in large part by the blood-brain barrier (BBB), which prevents adequate distribution of anti-cancer compounds to brain metastases. METHOD: In this study we used a novel screening method to identify candidate molecules that are well-suited to utilizing the BBB choline transporter for distribution into the brain parenchyma. RESULTS: From our screen we identified two compounds, Ch-1 and Ch-2 that were able to reduce the brain tumor burden in a murine mouse model of brain metastasis of breast cancer. These compounds also significantly increased the survival of mice by more than 10 days. Mechanistic studies indicated that Ch-1 is able to prevent the activation of the pro-survival mitogen-activated kinases (MAPKs) by osteoactivin (OA; Glycoprotein nonmetastatic melanoma protein B GPNMB). CONCLUSION: The results from this study show that nutrient transporter virtual screening is a viable novel alternative to traditional drug screening programs to identify anti-cancer compounds for the treatment of brain cancers.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2174/1568009617666161121123948" target="_blank" rel="noreferrer noopener">10.2174/1568009617666161121123948</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2017
ADME
Animals
Antineoplastic Agents/*therapeutic use
Apoptosis
Brain cancer
Brain Neoplasms/*drug therapy/pathology/*secondary
Breast Neoplasms/*pathology
Cell Line
Chemotherapy
CNS
Current cancer drug targets
Department of Anatomy & Neurobiology
distribution
Drug Discovery
Drug Resistance
Female
Geldenhuys Werner J
Griffith Jessica I G
Humans
Lockman Paul R
Mice
NEOMED College of Medicine
Safadi Fayez F
Sondag Gregory R
Terell-Hall Tori B
Tumor
Venishetty Vinay K
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1158/1940-6207.CAPR-08-0160" target="_blank" rel="noreferrer noopener">http://doi.org/10.1158/1940-6207.CAPR-08-0160</a>
Pages
409–418
Issue
5
Volume
2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials.
Publisher
An entity responsible for making the resource available
Cancer prevention research (Philadelphia, Pa.)
Date
A point or period of time associated with an event in the lifecycle of the resource
2009
2009-05
Subject
The topic of the resource
Animals; Antineoplastic Agents/*therapeutic use; Clinical Trials as Topic; Humans; Neoplasms/*prevention & control; Resveratrol; Stilbenes/*therapeutic use
Creator
An entity primarily responsible for making the resource
Bishayee Anupam
Description
An account of the resource
Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a dietary polyphenol derived from grapes, berries, peanuts, and other plant sources. During the last decade, resveratrol has been shown to possess a fascinating spectrum of pharmacologic properties. Multiple biochemical and molecular actions seem to contribute to resveratrol effects against precancerous or cancer cells. Resveratrol affects all three discrete stages of carcinogenesis (initiation, promotion, and progression) by modulating signal transduction pathways that control cell division and growth, apoptosis, inflammation, angiogenesis, and metastasis. The anticancer property of resveratrol has been supported by its ability to inhibit proliferation of a wide variety of human tumor cells in vitro. These in vitro data have led to numerous preclinical animal studies to evaluate the potential of this drug for cancer chemoprevention and chemotherapy. This review provides concise, comprehensive data from preclinical in vivo studies in various rodent models of human cancers, highlighting the related mechanisms of action. Bioavailability, pharmacokinetic, and potential toxicity studies of resveratrol in humans and ongoing interventional clinical trials are also presented. The conclusion describes directions for future resveratrol research to establish its activity and utility as a human cancer preventive and therapeutic drug.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1158/1940-6207.CAPR-08-0160" target="_blank" rel="noreferrer noopener">10.1158/1940-6207.CAPR-08-0160</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2009
Animals
Antineoplastic Agents/*therapeutic use
Bishayee Anupam
Cancer prevention research (Philadelphia, Pa.)
Clinical Trials as Topic
Humans
Neoplasms/*prevention & control
Resveratrol
Stilbenes/*therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/jn/131.1.158S" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/jn/131.1.158S</a>
Pages
158S–160S
Issue
1
Volume
131
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Evaluation of the in vitro and in vivo antitumor activities of vitamin C and K-3 combinations against human prostate cancer.
Publisher
An entity responsible for making the resource available
The Journal of nutrition
Date
A point or period of time associated with an event in the lifecycle of the resource
2001
2001-01
Subject
The topic of the resource
Animals; Antineoplastic Agents/*therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Ascorbic Acid/*therapeutic use; Humans; Male; Prostatic Neoplasms/*prevention & control; Vitamin K/*therapeutic use
Creator
An entity primarily responsible for making the resource
Jamison J M; Gilloteaux J; Taper H S; Summers J L
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/jn/131.1.158S" target="_blank" rel="noreferrer noopener">10.1093/jn/131.1.158S</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2001
Animals
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Ascorbic Acid/*therapeutic use
Gilloteaux J
Humans
Jamison J M
Male
Prostatic Neoplasms/*prevention & control
Summers J L
Taper H S
The Journal of nutrition
Vitamin K/*therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0272-6386(99)70329-x" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0272-6386(99)70329-x</a>
Pages
E8–E8
Issue
2
Volume
33
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Chronic lymphocytic leukemia-associated membranous glomerulopathy: remission with fludarabine.
Publisher
An entity responsible for making the resource available
American journal of kidney diseases : the official journal of the National Kidney Foundation
Date
A point or period of time associated with an event in the lifecycle of the resource
1999
1999-02
Subject
The topic of the resource
Antineoplastic Agents/*therapeutic use; B-Cell/*complications; Biopsy; Chronic; Female; Glomerulonephritis; Humans; Kidney/pathology; Leukemia; Lymphocytic; Membranous/diagnosis/*drug therapy/etiology; Vidarabine/*analogs & derivatives/therapeutic use
Creator
An entity primarily responsible for making the resource
Butty H; Asfoura J; Cortese F; Doyle M; Rutecki G
Description
An account of the resource
In some individuals, chronic lymphocytic leukemia (CLL) may be associated with glomerular disease from membranous nephropathy with resultant nephrotic syndrome. CLL is characterized by abnormal immunoregulation with a malignant clonal proliferation of lymphocytes. The association between the abnormal clone and nephrotic syndrome is suggested in some cases by the remission of proteinuria with a reduction in abnormal lymphocyte number after treatment with antineoplastic agents. For the first time, we describe a patient with CLL and associated membranous glomerulopathy whose nephrotic syndrome remitted after treatment with fludarabine, a new purine analogue used in the treatment of refractory CLL.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0272-6386(99)70329-x" target="_blank" rel="noreferrer noopener">10.1016/s0272-6386(99)70329-x</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
1999
American journal of kidney diseases : the official journal of the National Kidney Foundation
Antineoplastic Agents/*therapeutic use
Asfoura J
B-Cell/*complications
Biopsy
Butty H
Chronic
Cortese F
Department of Internal Medicine
Doyle M
Female
Glomerulonephritis
Humans
Kidney/pathology
Leukemia
Lymphocytic
Membranous/diagnosis/*drug therapy/etiology
NEOMED College of Medicine
Rutecki G
Vidarabine/*analogs & derivatives/therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1002/hed.23647" target="_blank" rel="noreferrer noopener">http://doi.org/10.1002/hed.23647</a>
Pages
644–649
Issue
5
Volume
37
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Phase II study of gefitinib in patients with advanced salivary gland cancers.
Publisher
An entity responsible for making the resource available
Head & neck
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-05
Subject
The topic of the resource
80 and over; Adenocarcinoma/drug therapy/mortality/pathology; adenoid cystic carcinoma; Adenoid Cystic/*drug therapy/mortality/pathology; Adult; Aged; Antineoplastic Agents/*therapeutic use; Carcinoma; Disease-Free Survival; Dose-Response Relationship; Drug; Drug Administration Schedule; Female; gefitinib; Gefitinib; Humans; Local/*drug therapy/mortality/pathology; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness/pathology; Neoplasm Recurrence; Neoplasm Staging; non-adenoid cystic carcinoma; Prognosis; Quinazolines/*therapeutic use; Remission Induction; response to therapy; salivary gland cancer; Salivary Gland Neoplasms/*drug therapy/mortality/pathology; Survival Analysis; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Jakob John A; Kies Merrill S; Glisson Bonnie S; Kupferman Michael E; Liu Diane D; Lee J Jack; El-Naggar Adel K; Gonzalez-Angulo Ana M; Blumenschein George R Jr
Description
An account of the resource
BACKGROUND: The purpose of this study was to determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. METHODS: We conducted a phase II study in adenoid cystic carcinoma (ACC) and non-ACC. Gefitinib was administered 250 mg orally daily. The primary endpoint was tumor response. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and disease control rates. EGFR and human epidermal growth factor receptor 2 (HER2) expression were evaluated and correlated with outcomes. RESULTS: Thirty-seven patients were enrolled in this study, and 36 were evaluable (18 with ACC and 18 with non-ACC). No responses were observed. Median PFS was 4.3 months and 2.1 months, and median OS was 25.9 months and 16 months for patients with ACC and non-ACC, respectively. The disease control rate at 8 weeks was higher in patients with ACC. No unexpected toxicities occurred. EGFR and HER2 overexpression did not correlate with outcomes. CONCLUSION: We did not observe significant clinical activity of gefitinib in advanced salivary gland cancer. NCT00509002.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/hed.23647" target="_blank" rel="noreferrer noopener">10.1002/hed.23647</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2015
80 and over
Adenocarcinoma/drug therapy/mortality/pathology
adenoid cystic carcinoma
Adenoid Cystic/*drug therapy/mortality/pathology
Adult
Aged
Antineoplastic Agents/*therapeutic use
Blumenschein George R Jr
Carcinoma
Department of Internal Medicine
Disease-Free Survival
Dose-Response Relationship
Drug
Drug Administration Schedule
El-Naggar Adel K
Female
Gefitinib
Glisson Bonnie S
Gonzalez-Angulo Ana M
Head & neck
Humans
Jakob John A
Kies Merrill S
Kupferman Michael E
Lee J Jack
Liu Diane D
Local/*drug therapy/mortality/pathology
Male
Maximum Tolerated Dose
Middle Aged
NEOMED College of Medicine
Neoplasm Invasiveness/pathology
Neoplasm Recurrence
Neoplasm Staging
non-adenoid cystic carcinoma
Prognosis
Quinazolines/*therapeutic use
Remission Induction
response to therapy
salivary gland cancer
Salivary Gland Neoplasms/*drug therapy/mortality/pathology
Survival Analysis
Treatment Outcome